BioDlink Ships First Bevacizumab Biosimilar to Colombia

BioDlink has successfully completed its first international shipment of the biosimilar bevacizumab injection to Colombia, collaborating with Kexing BioPharm on this significant milestone. The shipment was celebrated with a ceremony in Suzhou, China, where specially-decorated transport vehicles marked the occasion. Bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), is commonly used in cancer treatments, including metastatic colorectal cancer and non-squamous non-small cell lung cancer.

The global sales of bevacizumab injection reached an impressive USD 8.5 billion in 2023, according to market data. BioDlink’s journey into the Colombian market began when it received marketing approval from Colombia’s National Institute for Surveillance of Medicines and Foods (INVIMA) in July 2025. This initial shipment, which occurred approximately two months after the approval, not only showcases BioDlink’s operational efficiency but also validates its antibody commercialization framework and stringent production quality management.

Investment in Quality and Compliance

BioDlink boasts a manufacturing facility that spans 50,000 square meters, which has successfully passed EU Qualified Person (QP) audits for antibody drugs and antibody-drug conjugates (ADCs) five times over the past four years, with no critical defects identified. The company’s quality management system supports over 100 clinical projects globally, encompassing development, clinical filings, and manufacturing services across regions, including Europe and the United States.

In addition to its focus on quality, BioDlink has achieved Good Manufacturing Practice (GMP) certification in several countries, including Brazil, Colombia, Argentina, Egypt, Indonesia, Pakistan, and Thailand. Kexing BioPharm, the global licensee for bevacizumab in emerging markets, is currently undertaking regulatory filings in 35 countries in close collaboration with BioDlink. Notably, the GMP certification in Brazil, Colombia, and Argentina covers South America’s three most populous countries, representing approximately 71.4% of the continent’s population.

Addressing Cancer Needs in Colombia

Colombia faces a significant cancer burden, with an estimated 117,620 new cases reported in 2022, including 11,163 colorectal and 7,196 lung cancer cases. This context underscores the strategic importance of bringing bevacizumab to the market, particularly for treating metastatic colorectal cancer and non-squamous non-small cell lung cancer.

Since signing an international commercialization agreement with Kexing BioPharm in early 2022, both companies have established an efficient “R&D-manufacturing-access” model. This collaboration lays the groundwork for the future international launch of additional pharmaceutical products. BioDlink is dedicated to ensuring robust international manufacturing and supply chain reliability, while Kexing BioPharm utilizes its global channels to enhance localized market access.

BioDlink and Kexing BioPharm are committed to strengthening their global partnership to advance healthcare accessibility. Adhering to a philosophy of “Quality First, Innovation Driven, Success Together,” BioDlink aims to focus on emerging markets, including South America, South Asia, Southeast Asia, and Africa, with the goal of benefiting a broader patient population worldwide.

For more information on BioDlink and its initiatives, visit their website at [www.biodlink.com](https://www.biodlink.com/).